Most researchers trying to source CJC-1295 in Vera quickly find that local retail options are nearly impossible to find. What this means for Vera researchers is that your location matters far less than your ability to verify analytical documentation — and those quality checks are accessible to anyone. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis containing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. This guide gives Vera researchers the practical tools to verify sourcing options methodically and source high-purity CJC-1295 with confidence.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Vera researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are within acceptable research limits. For Vera researchers evaluating unfamiliar vendors: a modest first purchase to test the product before scaling up your order is standard practice in the community. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Vera
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; avoid repeatedly thawing and refreezing reconstituted peptide by aliquoting into single-use portions. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is unapproved for human therapeutic application and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
